We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Exopharm is a biotechnology business based in Australia. Exopharm shares (EX1) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Exopharm has a trailing 12-month revenue of around $4.2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $0.11 - $0.635 |
|---|---|
| 50-day moving average | $0.1839 |
| 200-day moving average | $0.3728 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.067 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.16
| 1 week (2022-06-16) | 10.34% |
|---|---|
| 1 month (2022-05-26) | 0.16 |
| 3 months (2022-03-25) | -47.54% |
| 6 months (2021-12-24) | -66.32% |
| 1 year (2021-06-25) | -69.23% |
|---|---|
| 2 years (2020-06-26) | -34.69% |
| 3 years (2019-06-26) | -61.90% |
| Revenue TTM | $4.2 million |
|---|---|
| Gross profit TTM | $61,104 |
| Return on assets TTM | -48.57% |
| Return on equity TTM | -97.38% |
| Profit margin | -242.77% |
| Book value | 0.072 |
| Market capitalisation | $23.6 million |
TTM: trailing 12 months
We're not expecting Exopharm to pay a dividend over the next 12 months.
Over the last 12 months, Exopharm 's shares have ranged in value from as little as $0.11 up to $0.635. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Exopharm 's is 1.2635. This would suggest that Exopharm 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, which enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
